<?xml version='1.0' encoding='utf-8'?>
<document id="20097249"><sentence text="Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions." /><sentence text="A series of studies were designed and carried out in order to explore the potential for the major human hepatic hydrolase, carboxylesterase 1 (hCES1), to serve as a target of metabolic inhibition by a variety of medications" /><sentence text=" The risk of adverse drug-drug interaction(s) is present when metabolic inhibitors are combined with known or suspected substrates of a given enzyme" /><sentence text=" In the present report the abundantly expressed hepatic enzyme, hCES1, was examined as a potential target of metabolic inhibition by a number of routinely prescribed medications" /><sentence text=" hCES1 has been seldom assessed in this regard despite its role in the metabolism and detoxification of many compounds" /><sentence text=" The psychostimulant methylphenidate (MPH) was chosen as an hCES1 selective substrate"><entity charOffset="21-36" id="DDI-PubMed.20097249.s6.e0" text="methylphenidate" /><entity charOffset="38-41" id="DDI-PubMed.20097249.s6.e1" text="MPH" /><pair ddi="false" e1="DDI-PubMed.20097249.s6.e0" e2="DDI-PubMed.20097249.s6.e0" /><pair ddi="false" e1="DDI-PubMed.20097249.s6.e0" e2="DDI-PubMed.20097249.s6.e1" /></sentence><sentence text=" In vitro studies were performed using previously developed cell lines which overexpress hCES1 with both p-nitrophenyl acetate and d-MPH serving as known substrates"><entity charOffset="105-126" id="DDI-PubMed.20097249.s7.e0" text="p-nitrophenyl acetate" /><entity charOffset="131-136" id="DDI-PubMed.20097249.s7.e1" text="d-MPH" /><entity charOffset="133-137" id="DDI-PubMed.20097249.s7.e2" text="MPH" /><pair ddi="false" e1="DDI-PubMed.20097249.s7.e0" e2="DDI-PubMed.20097249.s7.e0" /><pair ddi="false" e1="DDI-PubMed.20097249.s7.e0" e2="DDI-PubMed.20097249.s7.e1" /><pair ddi="false" e1="DDI-PubMed.20097249.s7.e0" e2="DDI-PubMed.20097249.s7.e2" /><pair ddi="false" e1="DDI-PubMed.20097249.s7.e1" e2="DDI-PubMed.20097249.s7.e1" /><pair ddi="false" e1="DDI-PubMed.20097249.s7.e1" e2="DDI-PubMed.20097249.s7.e2" /></sentence><sentence text=" Aripiprazole, perphenazine, thioridazine, and fluoxetine were determined to be the potent hCES1 inhibitors"><entity charOffset="1-13" id="DDI-PubMed.20097249.s8.e0" text="Aripiprazole" /><entity charOffset="15-27" id="DDI-PubMed.20097249.s8.e1" text="perphenazine" /><entity charOffset="29-41" id="DDI-PubMed.20097249.s8.e2" text="thioridazine" /><entity charOffset="47-57" id="DDI-PubMed.20097249.s8.e3" text="fluoxetine" /><pair ddi="false" e1="DDI-PubMed.20097249.s8.e0" e2="DDI-PubMed.20097249.s8.e0" /><pair ddi="false" e1="DDI-PubMed.20097249.s8.e0" e2="DDI-PubMed.20097249.s8.e1" /><pair ddi="false" e1="DDI-PubMed.20097249.s8.e0" e2="DDI-PubMed.20097249.s8.e2" /><pair ddi="false" e1="DDI-PubMed.20097249.s8.e0" e2="DDI-PubMed.20097249.s8.e3" /><pair ddi="false" e1="DDI-PubMed.20097249.s8.e1" e2="DDI-PubMed.20097249.s8.e1" /><pair ddi="false" e1="DDI-PubMed.20097249.s8.e1" e2="DDI-PubMed.20097249.s8.e2" /><pair ddi="false" e1="DDI-PubMed.20097249.s8.e1" e2="DDI-PubMed.20097249.s8.e3" /><pair ddi="false" e1="DDI-PubMed.20097249.s8.e2" e2="DDI-PubMed.20097249.s8.e2" /><pair ddi="false" e1="DDI-PubMed.20097249.s8.e2" e2="DDI-PubMed.20097249.s8.e3" /></sentence><sentence text=" A complementary animal study followed in vitro screening studies to further evaluate the inhibitory effect of aripiprazole on CES1 activity in FVB mice"><entity charOffset="111-123" id="DDI-PubMed.20097249.s9.e0" text="aripiprazole" /></sentence><sentence text=" The results suggest that the concurrent administration of racemic (i" /><sentence text="e" /><sentence text=" dl-) MPH with aripiprazole significantly increased the plasma concentrations of both total MPH as well as the less active l-isomer"><entity charOffset="15-27" id="DDI-PubMed.20097249.s12.e0" text="aripiprazole" /><entity charOffset="6-17" id="DDI-PubMed.20097249.s12.e1" text="MPH" /><entity charOffset="92-103" id="DDI-PubMed.20097249.s12.e2" text="MPH" /><pair ddi="false" e1="DDI-PubMed.20097249.s12.e1" e2="DDI-PubMed.20097249.s12.e1" /><pair ddi="false" e1="DDI-PubMed.20097249.s12.e1" e2="DDI-PubMed.20097249.s12.e0" /><pair ddi="false" e1="DDI-PubMed.20097249.s12.e1" e2="DDI-PubMed.20097249.s12.e2" /><pair ddi="false" e1="DDI-PubMed.20097249.s12.e0" e2="DDI-PubMed.20097249.s12.e0" /><pair ddi="false" e1="DDI-PubMed.20097249.s12.e0" e2="DDI-PubMed.20097249.s12.e2" /></sentence><sentence text=" The ratio of d-MPH and l-MPH plasma concentrations was significantly decreased in the mice treated with aripiprazole compared to the control animals, indicating an overall decrease of CES1 catalytic activity in aripiprazole treated animals"><entity charOffset="14-19" id="DDI-PubMed.20097249.s13.e0" text="d-MPH" /><entity charOffset="24-29" id="DDI-PubMed.20097249.s13.e1" text="l-MPH" /><entity charOffset="105-117" id="DDI-PubMed.20097249.s13.e2" text="aripiprazole" /><entity charOffset="212-224" id="DDI-PubMed.20097249.s13.e3" text="aripiprazole" /><entity charOffset="16-27" id="DDI-PubMed.20097249.s13.e4" text="MPH" /><entity charOffset="26-37" id="DDI-PubMed.20097249.s13.e5" text="MPH" /><pair ddi="false" e1="DDI-PubMed.20097249.s13.e0" e2="DDI-PubMed.20097249.s13.e0" /><pair ddi="false" e1="DDI-PubMed.20097249.s13.e0" e2="DDI-PubMed.20097249.s13.e4" /><pair ddi="false" e1="DDI-PubMed.20097249.s13.e0" e2="DDI-PubMed.20097249.s13.e1" /><pair ddi="false" e1="DDI-PubMed.20097249.s13.e0" e2="DDI-PubMed.20097249.s13.e5" /><pair ddi="false" e1="DDI-PubMed.20097249.s13.e0" e2="DDI-PubMed.20097249.s13.e2" /><pair ddi="false" e1="DDI-PubMed.20097249.s13.e0" e2="DDI-PubMed.20097249.s13.e3" /><pair ddi="false" e1="DDI-PubMed.20097249.s13.e4" e2="DDI-PubMed.20097249.s13.e4" /><pair ddi="false" e1="DDI-PubMed.20097249.s13.e4" e2="DDI-PubMed.20097249.s13.e1" /><pair ddi="false" e1="DDI-PubMed.20097249.s13.e4" e2="DDI-PubMed.20097249.s13.e5" /><pair ddi="false" e1="DDI-PubMed.20097249.s13.e4" e2="DDI-PubMed.20097249.s13.e2" /><pair ddi="false" e1="DDI-PubMed.20097249.s13.e4" e2="DDI-PubMed.20097249.s13.e3" /><pair ddi="false" e1="DDI-PubMed.20097249.s13.e1" e2="DDI-PubMed.20097249.s13.e1" /><pair ddi="false" e1="DDI-PubMed.20097249.s13.e1" e2="DDI-PubMed.20097249.s13.e5" /><pair ddi="false" e1="DDI-PubMed.20097249.s13.e1" e2="DDI-PubMed.20097249.s13.e2" /><pair ddi="false" e1="DDI-PubMed.20097249.s13.e1" e2="DDI-PubMed.20097249.s13.e3" /><pair ddi="false" e1="DDI-PubMed.20097249.s13.e5" e2="DDI-PubMed.20097249.s13.e5" /><pair ddi="false" e1="DDI-PubMed.20097249.s13.e5" e2="DDI-PubMed.20097249.s13.e2" /><pair ddi="false" e1="DDI-PubMed.20097249.s13.e5" e2="DDI-PubMed.20097249.s13.e3" /><pair ddi="false" e1="DDI-PubMed.20097249.s13.e2" e2="DDI-PubMed.20097249.s13.e2" /><pair ddi="false" e1="DDI-PubMed.20097249.s13.e2" e2="DDI-PubMed.20097249.s13.e3" /></sentence><sentence text=" Additionally, a quantitative structure-activity relationship based analysis identified a number of structural similarities of CES1 inhibitors" /><sentence text=" In conclusion, drug-drug interactions with MPH are likely mediated via CES1 inhibition as a result of concomitant drug therapies"><entity charOffset="44-46" id="DDI-PubMed.20097249.s15.e0" text="MPH" /></sentence><sentence text=" CES1 inhibition represents an overlooked and little studied source of variability in MPH disposition, tolerability, and response"><entity charOffset="86-88" id="DDI-PubMed.20097249.s16.e0" text="MPH" /></sentence><sentence text="" /></document>